Zogenix (ZGNX) Zohydro ER Fails to Win FDA Panel Backing
- Banks drag Wall Street lower as growth fears, rate outlook weigh
- AIG (AIG) Misses Q4 EPS by 19c; Raises Buyback to $5B, Announces Dividend Increase
- CBS Corp. (CBS) Reports In-Line Q4 EPS
- JPMorgan's Dimon buys more than $25 million of company stock
- After-Hours Stock Movers 02/11: (GRPN) (COLM) (ELLI) Higher; (NUS) (SCSS) (ATVI) Lower (more...)
Zogenix (Nasdaq: ZGNX) Zohydro ER fails to win FDA panel backing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hercules Offshore (HERO) Will Explore Strategic Options
- Barrett Business Services (BBSI) Announces Favorable Outcome of Independent Investigation
- Pandora (P) trading paused for volatility
Create E-mail Alert Related CategoriesCorporate News, FDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!